Alpha-7 nAChR Agonist Restores CFTR Ion Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Deterioration of mucus clearance mechanisms contributes significantly to the pathogenesis of respiratory diseases, as evidenced by decreased function of the cystic fibrosis transmembrane conductance regulator (CFTR) channels and associated ion transport issues, leading to impaired airway hydration and mucociliary clearance.
Innovation Solution
Administration of an α-7 nicotinic acetylcholine receptor (nAChR) agonist, such as GTS-21, to restore CFTR function and enhance mucus clearance by promoting α-7 nAChR signaling, thereby improving airway surface hydration and mucociliary transport.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CFTR channel function is impaired, then ion transport is disrupted, but airway hydration and mucus clearance are maintained
Solution Approach 1:
The patent uses α-7 nAChR agonists as intermediary substances that mediate between the impaired CFTR channel function and the desired mucus clearance outcome. The agonist binds to and activates α-7 nAChR receptors on airway epithelial cells, triggering a signaling cascade that compensates for defective CFTR-mediated chloride transport and restores mucociliary clearance function.
Solution Approach 2:
The patent changes the physiological parameters of airway epithelial cell function by introducing exogenous α-7 nAChR agonists. This alters the receptor activation state, intracellular calcium levels, and downstream signaling pathways to compensate for CFTR dysfunction and improve mucus transport properties.
2Productivity
If mucus clearance is deteriorated, then respiratory disease risk increases, but conventional treatments have limited efficacy
Solution Approach 1:
The patent converts the harmful effect of impaired mucus clearance (which leads to respiratory disease) into a beneficial therapeutic outcome by using α-7 nAChR agonists. These compounds activate alternative signaling pathways that compensate for CFTR dysfunction, transforming the pathological state into a treatable condition with improved mucus transport and reduced disease risk.
3Reliability
If α-7 nAChR agonist is administered, then CFTR function is restored, but drug dosage and administration protocols must be optimized
Solution Approach 1:
The patent employs partial agonist activity of α-7 nAChR agonists to achieve sufficient CFTR function restoration without requiring maximal drug doses. This partial activation approach provides therapeutic benefit while potentially reducing side effects and simplifying dosage optimization compared to full agonist requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The α-7 nAChR agonist effectively restores CFTR-dependent ion transport and mucociliary clearance in subjects with decreased mucus clearance, offering therapeutic benefits for respiratory disorders like cystic fibrosis and chronic obstructive pulmonary disease (COPD) by enhancing airway hydration and mucus transport.
Implementation Method 1
administering to the subject an effective amount of α-7 nicotinic acetylcholine receptor (nAChR) agonist
Implementation Method 2
restores CFTR function and enhance mucus clearance by promoting α-7 nAChR signaling, thereby improving airway surface hydration and mucociliary transport
Data Source
AI summary
Provided herein are methods of increasing mucus clearance in a subject having decreased mucus clearance. Also provided are methods of treating or preventing a respiratory disorder.